MRI for identification of progression in brain tumors: from morphology to function

For monitoring of brain tumors, it is crucial to identify progression or treatment failure early during follow-up to change treatment schemes and, thereby, optimize patient outcome. In the past years, several areas within the field of magnetic resonance (MR) have seen considerable advances: modern contrast media, advanced morphologic approaches and several functional techniques, for example, in the visualization of tumor perfusion or tumor cell metabolism. This review presents these recent advances by introducing the different techniques and outlining their benefit for identification of progression in brain tumors, with a focus on gliomas, metastases and meningiomas. After radiotherapy, MR spectroscopy helps to more accurately discriminate between radiation necrosis and glioma progression. In low-grade gliomas, perfusion MR techniques enable a more sensitive detection of anaplastic transformation than conventional MRI. Modern contrast media, as well as diffusion tensor imaging, allow for an improved tumor delineation and assessment of tumor extension. We will also highlight the biological background of these techniques, their applicability and current limitations. In conclusion, modern MRI techniques have been developed that are on the doorstep to be integrated in clinical routine.

[1]  J D Pickard,et al.  Diffusion tensor imaging of brain tumours at 3T: a potential tool for assessing white matter tract invasion? , 2003, Clinical radiology.

[2]  Stephan E Maier,et al.  Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B Stieltjes,et al.  Detection of tumour infiltration in axonal fibre bundles using diffusion tensor imaging , 2005, The international journal of medical robotics + computer assisted surgery : MRCAS.

[4]  Tristan Barrett,et al.  MRI of tumor angiogenesis , 2007, Journal of magnetic resonance imaging : JMRI.

[5]  P Bachert,et al.  Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. , 2001, AJNR. American journal of neuroradiology.

[6]  M. Essig,et al.  MR-Perfusions- und spektroskopische Bildgebung bei WHO-Grad-II-Astrozytomen , 2007, Der Radiologe.

[7]  F. Giangaspero Emerging Tumor Entities and Variants of CNS Neoplasms , 2004, Journal of neuropathology and experimental neurology.

[8]  V. Tronnier,et al.  Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging , 2003, Neuroscience Letters.

[9]  L. Calabi,et al.  Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. , 1999, Journal of computer assisted tomography.

[10]  C. Kuhl,et al.  Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T--Initial Experience. , 2005, Radiology.

[11]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[12]  P. Black,et al.  Epidemiology of intracranial meningioma. , 2005, Neurosurgery.

[13]  J. Voges,et al.  Imaging in Gene Therapy of Patients with Glioma , 2003, Journal of Neuro-Oncology.

[14]  B. Rosen,et al.  Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. , 1999, Journal of neurosurgery.

[15]  M V Knopp,et al.  Dynamic contrast-enhanced magnetic resonance imaging in oncology. , 2001, Topics in magnetic resonance imaging : TMRI.

[16]  Bjoern H Menze,et al.  Optimal classification of long echo time in vivo magnetic resonance spectra in the detection of recurrent brain tumors , 2006, NMR in biomedicine.

[17]  J. Debus,et al.  Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy , 2004, Neuroradiology.

[18]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[19]  Mauricio Castillo,et al.  MR spectroscopy of brain tumors. , 2003, Magnetic resonance imaging clinics of North America.

[20]  Bradford A Moffat,et al.  The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. , 2006, Neoplasia.

[21]  P. Kleihues,et al.  Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.

[22]  M. Décorps,et al.  Methodology of brain perfusion imaging , 2001, Journal of magnetic resonance imaging : JMRI.

[23]  Marc-André Weber,et al.  Mimicking the human expert: Pattern recognition for an automated assessment of data quality in MR spectroscopic images , 2008, Magnetic resonance in medicine.

[24]  Michael Bock,et al.  3D radial projection technique with ultrashort echo times for sodium MRI: Clinical applications in human brain and skeletal muscle , 2007, Magnetic resonance in medicine.

[25]  M P Lichy,et al.  Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors , 2006, Neurology.

[26]  G. Fuller,et al.  The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. , 1998, Surgical neurology.

[27]  Elias R Melhem,et al.  Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience. , 2007, Radiology.

[28]  Mark E Mullins,et al.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. , 2005, AJNR. American journal of neuroradiology.

[29]  J Debus,et al.  Assessment of brain metastases with dynamic susceptibility-weighted contrast-enhanced MR imaging: initial results. , 2003, Radiology.

[30]  S. Cherry,et al.  Simultaneous in vivo positron emission tomography and magnetic resonance imaging , 2008, Proceedings of the National Academy of Sciences of the United States of America.

[31]  N. Hopf,et al.  Contribution of diffusion tensor imaging to delineation of gliomas and glioblastomas , 2004, Journal of magnetic resonance imaging : JMRI.

[32]  Marc-André Weber,et al.  Semi-supervised Tumor Detection in Magnetic Resonance Spectroscopic Images Using Discriminative Random Fields , 2007, DAGM-Symposium.

[33]  I. Wilkinson,et al.  Influence of Human Serum Albumin on Longitudinal and Transverse Relaxation Rates (R1 and R2) of Magnetic Resonance Contrast Agents , 2006, Investigative radiology.

[34]  Daniel P Barboriak,et al.  Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. , 2006, Radiology.

[35]  Xavier Golay,et al.  Amide proton transfer imaging of human brain tumors at 3T , 2006, Magnetic resonance in medicine.

[36]  M E Moseley,et al.  New magnetic resonance imaging methods for cerebrovascular disease: Emerging clinical applications , 2000, Annals of neurology.

[37]  L D Lunsford,et al.  Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. , 1993, Journal of neurosurgery.

[38]  Robert C Brasch,et al.  Dynamic contrast‐enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti‐angiogenic therapy in a xenograft model of glioblastoma multiforme , 2002, Journal of magnetic resonance imaging : JMRI.

[39]  M. Bock,et al.  Assessment of Gadobenate Dimeglumine for Magnetic Resonance Angiography: Phase I Studies , 2002, Investigative radiology.

[40]  B A Kall,et al.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.

[41]  R. Ouwerkerk Sodium magnetic resonance imaging: from research to clinical use. , 2007, Journal of the American College of Radiology : JACR.

[42]  T. Koepsell,et al.  Epidemiology of intracranial meningioma , 1993, Cancer.

[43]  W. Heiss,et al.  Molecular Imaging of Gliomas , 2002, Molecular imaging.

[44]  I. Wilkinson,et al.  Dexamethasone and Enhancing Solitary Cerebral Mass Lesions: Alterations in Perfusion and Blood-tumor Barrier Kinetics Shown by Magnetic Resonance Imaging , 2006, Neurosurgery.

[45]  C. Beaulieu,et al.  Determinants of anisotropic water diffusion in nerves , 1994, Magnetic resonance in medicine.

[46]  M. Leach,et al.  Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy , 2004, British Journal of Cancer.

[47]  Frederik L. Giesel,et al.  Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors , 2006, Neurology.

[48]  K. Zierler,et al.  On the theory of the indicator-dilution method for measurement of blood flow and volume. , 1954, Journal of applied physiology.

[49]  G Johnson,et al.  Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. , 2000, AJNR. American journal of neuroradiology.

[50]  F. Cavagna,et al.  Gd‐BOPTA/Dimeg: Experimental disease imaging , 1991, Magnetic resonance in medicine.

[51]  Peter McGraw,et al.  Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. , 2004, Radiology.

[52]  A. Padhani Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.

[53]  Matthias Günther,et al.  Comparison of Arterial Spin-Labeling Techniques and Dynamic Susceptibility-Weighted Contrast-Enhanced MRI in Perfusion Imaging of Normal Brain Tissue , 2003, Investigative radiology.

[54]  K. Herfarth,et al.  PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  H. Minn PET and SPECT in low-grade glioma. , 2005, European journal of radiology.

[56]  J. Dichgans,et al.  One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.

[57]  James M Provenzale,et al.  Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. , 2002, Radiology.

[58]  Heinz-Otto Peitgen,et al.  Diffusion tensor imaging in primary brain tumors: Reproducible quantitative analysis of corpus callosum infiltration and contralateral involvement using a probabilistic mixture model , 2006, NeuroImage.

[59]  Thomas L Chenevert,et al.  Diffusion imaging: insight to cell status and cytoarchitecture. , 2006, Neuroimaging clinics of North America.

[60]  M. Maeda,et al.  Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability , 2005, European Radiology.

[61]  J. O'fallon,et al.  Triple-dose Contrast/magnetization Transfer Suppressed Imaging of ‘non-enhancing’ Brain Gliomas , 2002, Journal of Neuro-Oncology.

[62]  V. Stieber Low-grade gliomas , 2001, Current Treatment Options in Oncology.

[63]  M. Knopp,et al.  Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imaging , 2003, Journal of magnetic resonance imaging : JMRI.

[64]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.

[65]  H. Kauczor,et al.  Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. , 2006, Chest.

[66]  B. Hiremagalur,et al.  Gadolinium and nephrogenic systemic fibrosis: Association or causation (Review Article) , 2008, Nephrology.

[67]  W. Yuh,et al.  Contrast-Enhanced Magnetic Resonance Imaging of Central Nervous System Tumors: Agents, Mechanisms, and Applications , 2006, Topics in magnetic resonance imaging : TMRI.

[68]  C. Colosimo,et al.  Detection of Intracranial Metastases: A Multicenter, Intrapatient Comparison of Gadobenate Dimeglumine-Enhanced MRI with Routinely Used Contrast Agents at Equal Dosage , 2001, Investigative radiology.

[69]  J. E. Tanner,et al.  Spin diffusion measurements : spin echoes in the presence of a time-dependent field gradient , 1965 .

[70]  C. Zimmer,et al.  Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. , 2003, Radiology.

[71]  Glyn Johnson,et al.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. , 2002, Radiology.

[72]  P. Kirchner,et al.  Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. , 1994, AJR. American journal of roentgenology.

[73]  G Brix,et al.  Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: Initial results , 1998, Journal of magnetic resonance imaging : JMRI.

[74]  C. Eskey,et al.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. , 2004, AJNR. American journal of neuroradiology.

[75]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[76]  Heinz-Peter Schlemmer,et al.  Follow-up gliomas after radiotherapy: 1H MR spectroscopic imaging for increasing diagnostic accuracy , 2005, Neuroradiology.

[77]  S. Delorme,et al.  Applications of MRS in the evaluation of focal malignant brain lesions , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[78]  A. Walker,et al.  Epidemiology of brain tumors , 1985, Neurology.

[79]  M. Essig,et al.  Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[80]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.

[81]  M P Lichy,et al.  [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors]. , 2006, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[82]  W. Heiss,et al.  Imaging-guided gene therapy of experimental gliomas. , 2007, Cancer research.

[83]  Glyn Johnson,et al.  Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. , 2006, Radiology.

[84]  G. Morana,et al.  Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. , 2005, Radiology.

[85]  U. Haberkorn,et al.  PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[86]  M Takahashi,et al.  Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. , 2000, AJNR. American journal of neuroradiology.

[87]  G Brix,et al.  An optimized workflow for the integration of biological information into radiotherapy planning: experiences with T1w DCE-MRI , 2005, Physics in medicine and biology.

[88]  Soonmee Cha,et al.  Perfusion MR Imaging of Brain Tumors , 2004, Topics in magnetic resonance imaging : TMRI.

[89]  K. Herfarth,et al.  Detection of tumour progression in the follow-up of irradiated low-grade astrocytomas: comparison of 3-[123I]iodo-α-methyl-L-tyrosine and 99mTc-MIBI SPET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[90]  J. Debatin,et al.  Gadobenate dimeglumine (MultiHance®) for magnetic resonance angiography: review of literature , 2003, European Radiology.

[91]  M. Knopp,et al.  Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2004, Radiology.

[92]  H. Kauczor,et al.  Assessment of Irradiated Brain Metastases by Means of Arterial Spin-Labeling and Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MRI: Initial Results , 2004, Investigative radiology.

[93]  R. Strecker,et al.  Vessel size imaging in humans , 2005, Magnetic resonance in medicine.

[94]  M. Knopp,et al.  Intracranial meningeomas: time- and dose-dependent effects of irradiation on tumor microcirculation monitored by dynamic MR imaging. , 1997, Magnetic resonance imaging.

[95]  Michael H Lev,et al.  Dynamic magnetic resonance perfusion imaging of brain tumors. , 2004, The oncologist.

[96]  W. Yuh,et al.  The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. , 1995, AJNR. American journal of neuroradiology.

[97]  K. Ohata,et al.  Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? , 2003, Journal of neurosurgery.

[98]  G. Pearlson,et al.  Diffusion Tensor Imaging and Axonal Tracking in the Human Brainstem , 2001, NeuroImage.

[99]  M. Bastin,et al.  Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[100]  C. Plathow,et al.  Metabolische Bildgebung zur Verlaufskontrolle stereotaktisch bestrahlter Gliome: Wertigkeit der 1H-MR-Spektroskopie im Vergleich zur FDG-PET und IMT-SPECT , 2004 .

[101]  N. Hylton Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.